Content area
Full Text
WASHINGTON The billion-dollar direct-to-consumer advertising industry s impact on prescription drug costs and utilization is being carefully reviewed by congressional and regulatory officials.
A Food and Drug Administration official said the agency currently is finalizing surveys that will be given to healthcare consumers and physicians in order to measure their attitudes and reactions over DTC ads.
Officials from the Federal Trade Commission s Bureau of Economics, Consumer Protection and Policy Planning strongly backed the FDA s survey proposal at an Office of Management and Budget meeting late last month.